IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 63
- Registration Number
- NCT00210457
- Locations
- 🇨🇭
Centre Hospitalier Vaudois, Lausanne, Switzerland
🇫🇷Chu de Bicêtre, Le Kremlin Bicêtre, France
🇫🇷Hôpital du Bocage, Dijon, France
Post Marketing Surveillance Study of Dysport
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 783
- Registration Number
- NCT00210431
- Locations
- 🇫🇷
Hopital Purpan, Toulouse, France
🇫🇷Centre Hospitalier Saint Esprit, Agen, France
🇫🇷Hopital Timone Adultes, Marseille, France
Somatuline Autogel: Acromegaly Self/Partner Injection Study
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT00149188
- Locations
- 🇬🇧
Michael White Centre Diabetes & Endocrinology, Hull Royal Infirmary, Hull, East Yorkshire, United Kingdom
🇬🇧Department of Endocrinology, The Royal Free Hospital, Hampstead, London, United Kingdom
🇬🇧Dept of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 24
- Registration Number
- NCT00149240
- Locations
- 🇪🇸
University Hospital of Alcorcón, Madrid, Spain
🇪🇸University Hospital "La Fe". Valencia, Valencia, Spain
🇪🇸University Hospital "Vall d 'Hebrón". Barcelona, Barcelona, Spain
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 381
- Registration Number
- NCT00134810
- Locations
- 🇵🇹
Hospital de Santa Maria, Lisbon, Portugal
🇩🇪Clinic for Neurology, Westfalische Wilhelmsuniversitat, Munster, Germany
🇩🇪Schmerzzentrum Frankfurt, Frankfurt am Main, Germany
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
- Conditions
- Interventions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 45
- Registration Number
- NCT00125190
- Locations
- 🇺🇸
Ipsen, Brisbane, California, United States
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
- Conditions
- Interventions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 137
- Registration Number
- NCT00125164
- Locations
- 🇺🇸
Ipsen (formerly Tercica), Brisbane, California, United States
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 4
- Registration Number
- NCT00092287
- Locations
- 🇺🇸
Larry Kvols, MD, Tampa, Florida, United States
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
- Conditions
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 9
- Registration Number
- NCT00080015